Janux Therapeutics (JANX) Liabilities and Shareholders Equity (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $1.0 billion in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.0 billion, down 2.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 billion (up 16.81% YoY), and the FY2025 annual result was $1.0 billion, down 5.65% from the prior year.
• Liabilities and Shareholders Equity advanced to $1.0 billion in Q1 2026 per JANX's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.1 billion in Q4 2024 and troughed at $341.5 million in Q2 2023.
• A 5-year average of $660.6 million and a median of $689.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity declined 11.38% in 2023, then soared 179.05% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $364.0 million in 2022, then grew by 4.5% to $380.4 million in 2023, then soared by 179.05% to $1.1 billion in 2024, then retreated by 5.65% to $1.0 billion in 2025, then rose by 2.66% to $1.0 billion in 2026.
• Business Quant data shows JANX's Liabilities and Shareholders Equity at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.